GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China

Stock News

04/17

On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1177937236"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177937236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177937236?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177937236","market":"fut","top_or_hot":-1,"title":"GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China","media":"Stock News","content":"<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-17 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1177937236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177937236","pubTimestamp":1776415459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSKH":"GSK plc ADRhedged","BK4588":"碎股","IPOS":"Renaissance International IPO ETF","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克"},"translate_title":"葛兰素史克Belantamab Mafodotin在中国获上市批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":1,"GSK":1,"IPOS":1,"GSK.UK":1},"content_text":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}